Optiver Holding’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$46.2M Sell
1,256,300
-1,552,000
-55% -$73.5M 0.02% 193
2025
Q4
$143M Buy
2,808,300
+896,900
+47% +$45.9M 0.05% 92
2025
Q3
$106M Buy
1,911,400
+1,168,300
+157% +$68.4M 0.04% 87
2025
Q2
$51.3M Buy
743,100
+133,000
+22% +$9.05M 0.02% 106
2025
Q1
$42.4M Buy
610,100
+80,200
+15% +$6.62M 0.02% 102
2024
Q4
$45.6M Buy
529,900
+204,800
+63% +$22.1M 0.02% 106
2024
Q3
$38.7M Sell
325,100
-199,000
-38% -$26.5M 0.02% 123
2024
Q2
$74.8M Sell
524,100
-214,100
-29% -$28.4M 0.04% 101
2024
Q1
$94.8M Buy
738,200
+603,000
+446% +$71.8M 0.05% 109
2023
Q4
$14M Sell
135,200
-315,200
-70% -$31.2M 0.01% 258
2023
Q3
$41M Sell
450,400
-124,000
-22% -$10.9M 0.03% 162
2023
Q2
$46.5M Buy
574,400
+65,600
+13% +$5.36M 0.03% 158
2023
Q1
$40.5M Buy
508,800
+336,200
+195% +$23.8M 0.03% 181
2022
Q4
$11.7M Buy
172,600
+36,000
+26% +$2.11M 0.01% 230
2022
Q3
$6.8M Sell
136,600
-48,600
-26% -$2.6M 0.01% 195
2022
Q2
$10.3M Buy
+185,200
New +$10.3M 0.01% 159

Other funds holding NVO

Optiver Holding's NVO Position: Q1 2026 in Review

Optiver Holding sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 983,717 shares — an estimated $46.6M sold.

Optiver Holding first reported a position in NVO in Q3 2021 and held it in 14 quarters. The position peaked at $50.1M in Q4 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Optiver Holding reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Optiver Holding sold 983,717 Novo Nordisk shares in Q1 2026, an estimated $46.6M.
  • Optiver Holding first reported a position in Novo Nordisk in Q3 2021 and held it in 14 quarters.
  • Optiver Holding's Novo Nordisk position peaked at $50.1M in Q4 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.